CytomX Therapeutics (CTMX) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 17, 2026, with virtual participation available to shareholders.

• Shareholders are encouraged to review proxy materials and vote by June 16, 2026.

Voting matters and shareholder proposals

• Election of two directors, Matthew P. Young and Elaine V. Jones, Ph.D., for terms expiring at the 2029 annual meeting.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Amendment to increase authorized common stock from 300,000,000 to 600,000,000 shares.

• Amendments to the 2015 Equity Incentive Plan and Employee Stock Purchase Plan.

• Nonbinding advisory vote on executive compensation and on the frequency of future say-on-pay votes.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals and nominees.